News
Potential Best-in-Class TEAD Autopalmitoylation Inhibitor Supported by Promising Clinical Data SAN MATEO, Calif., July 30, 2025 /PRNewswire/ -- Vivace ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback